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Immunomodulatory effects of 14-member macrolides, namely erythromycin (EM) and 
clarithromycin (CAM), have been reported in chronic respiratory infectious diseases. It has 
been suggested that 14-member macrolides have immunomodulatory effects on various lung 
cells such as alveolar macrophages. Interleukin (IL)-10 is an immunomodulatory cytokine 
that performs an irreplaceable role in negatively regulating inflammation, primarily via a 
mechanism that selectively blocks the expression of pro-inflammatory genes. It activates sig-
nal transducer and activator of transcription (STAT)-3, and subsequently induces the suppres-
sor of cytokine signaling-3 (SOCS-3), resulting in the resolution of inflammatory response in 
macrophages. However, it has been still unclear whether 14-member macrolides exert immu-
nomodulatory effects via IL-10 signaling pathway. We aimed to evaluate whether 14-member 
macrolides affect the IL-10 signaling pathway. The RAW264.7 macrophage cell line was pre-
treated with EM or CAM, and stimulated with lipopolysaccharide (LPS). The levels of IL-10, 
IL-10 receptor, phosphorylated (p) STAT-3, and SOCS-3 were determined by RT-PCR, 
ELISA and immunoblotting. We observed increased levels of IL-10, p-STAT-3 and SOCS-3 
in the treated cells. In addition, while the levels of tumor necrosis factor-α 6 h after LPS 
stimulation was equal between vehicle-treated and CAM-treated macrophage cells, those of 
CAM-treated cells were repressed 36 h following LPS stimulation, compared with those of 
the control cells. Therefore, the 14-member macrolides may initiate an early resolution of 
inflammation, in part, via the enhancement of the IL-10/STAT-3/SOCS-3 pathway. 
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Macrolide antibiotics are a group of 
antibiotics whose activity stems from the 
presence of a macrolide ring, a large 
macrocyclic lactone ring to which one or 
more deoxy sugars, usually cladinose and 
desosamine, may be attached (Jain and 
Danziger, 2004). Fourteen, fifteen, and six-
teen-membered lactone ring macrolides are 
available for clinical use. In particular, 14-
member macrolides, such as erythromycin 
(EM) and clarithromycin (CAM), are 
widely used in patients with respiratory 
infections (Wierzbowski et al., 2006). 
Diffuse panbronchiolitis (DPB) is a res-
piratory disease observed in the Asian 
population (Azuma and Kudoh, 2006; 
Keicho and Kudoh, 2002). Prior to the dis-
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covery of long term EM therapy, DPB was 
an untreatable disease, which resulted in a 
lower respiratory infection from Haemophi-
lus influenzae or Pseudomonas aeruginosa, 
and many patients with DPB died due to 
their progressive respiratory failure. Kudoh 
et al. reported that the long-term use of EM 
in these patients improved their chest X-
rays and lung functions, and resulted in a 
vast improvement in their survival (Kudoh 
et al., 1998). Similar therapeutic effects of 
CAM have been reported in DPB patients 
(Kadota et al., 2003). 
The therapeutic mechanism of macro-
lides in DPB is not fully understood. The 
mechanism appears to be independent of 
the antibiotic effect of macrolides because 
their therapeutic benefit in DPB is observed 
at a dosage below the standard antibiotic 
dosage (Azuma and Kudoh, 2006; Keicho 
and Kudoh, 2002). Accumulating evidence 
suggests that an important mechanism in 
macrolide therapy for DPB may be immu-
nomodulatory effects (Azuma and Kudoh, 
2006). We previously demonstrated that 
CAM suppresses IL-8 production via sup-
pression of AP-1 activity in bronchial 
epithelial cells (Abe et al., 2000). Others 
have shown that 14-member macrolides 
exert immunomodulatory effects on lung 
epithelial cells (Shinkai et al., 2006). 
Alveolar macrophages are resident im-
mune cells that play an important role in 
host defense and inflammation in the lung 
(Shibata et al., 2001). Invading pathogens 
are recognized via pathogen recognition 
receptors such as toll-like receptor-2, -4, 
scavenger receptors, and mannose recep-
tors, and are phagocytosed. These macro-
phages also produce pro-inflammatory cy-
tokines and chemokines, which accumulate 
and activate other inflammatory cells such 
as neutrophils and T lymphocytes (Akira, 
2003; Plowden et al., 2004). Macrolide an-
tibiotics reportedly repress the production 
of pro-inflammatory cytokines in alveolar 
macrophages (Hodge et al., 2006). 
Among the cytokines induced in the in-
flamed lung, interleukin (IL)-10 is a potent 
anti-inflammatory cytokine predominantly 
produced by the alveolar macrophages 
(Moore et al., 2001). IL-10 suppresses in-
flammation via the repression of nuclear 
factor-κB (Shames et al., 1998), and via the 
activation of the suppressor of cytokine 
signaling 3 (SOCS-3) (Yoshimura et al., 
2003, 2005). Following the binding of IL-
10 to its receptor, the signal transducer and 
activator of transcription (STAT)-3 is phos-
phorylated. Subsequently, SOCS-3 is in-
duced and it inhibits pro-inflammatory cy-
tokine signals (Yoshimura et al., 2003, 
2005). Through this pathway, IL-10 also 
represses the production of pro-
inflammatory cytokines such as tumor ne-
crosis factor (TNF)-α in macrophages 
(Yoshimura et al., 2003, 2005). Although 
CAM reportedly augments the expression 
of IL-10 in human monocytes (Morikawa et 
al., 1996), it is unknown whether the im-
munomodulatory effects of 14-member 
macrolides on macrophages are associated 
with this IL-10 pathway.  
With this in mind we sought to clarify 
the effect of 14-member macrolides on the 
expression of IL-10 in a macrophage cell 
line. We showed that the production of IL-
10 by macrophages pretreated with EM and 
CAM was enhanced upon stimulation with 
lipopolysaccharide (LPS), followed by 
STAT-3 phosphorylation and SOCS-3 up-
regulation. The induction of IL-10 may thus 
be involved in the immunomodulatory ef-
fects of 14-member macrolide antibiotics 
on macrophages. 
 
MATERIALS AND METHODS 
Cell culture. The mouse macrophage 
cell line RAW264.7 was grown in DMEM 
with 10 % FBS, 100 U/mL penicillin, and 
100 U/mL streptomycin in an atmosphere 
of 5 % CO2 and 95 % air at 37 °C. 
Pretreatment with macrolides and 
stimulation with LPS. RAW264.7 cells 
were seeded onto a 6 cm dish at 1×105 
cells/dish and were treated with vehicle 
(ethanol), EM (Sigma, St. Louis, MO, 
USA: 1 or 10 µg/mL) or CAM (Sigma: 1 or 
10 µg/mL) for 3 days. Subsequently, the 
cells were stimulated with LPS (Sigma: 
20 ng/mL) for 4 h (total RNA isolation), 8 h 
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(cell lysate preparation), or 24 h (super-
natant collection). 
RT-PCR. Total RNA was extracted 
from cells using TRIzol regent (Invitrogen, 
Carlsbad, CA, USA), according to the 
manufacturer’s protocol. Reverse transcrip-
tion (RT) was performed using SuperScript 
II reverse transcriptase (Invitrogen) and 
gene expression was assessed by RT-PCR. 
Sequences of the specific primers used are 
as follows: for IL-10 (forward; CTT CAG 
CCA GGT GAA GAC, reverse; TGG AGT 
CCA GCA GAC TCA AT), for IL-10 re-
ceptor (R) (forward; AGG CAG AGG CAG 
CAG GCC CAG CAG AAT GCT, reverse; 
TGG AGC CTG GCT AGC TGG TCA 
CAG TAG GTC T), for SOCS-3 (forward; 
ACC AGC GCC ACT TCT TCA CG, re-
verse; GTG GAG CAT CAT ACT GAT 
CC), and for GAPDH (forward; ACT CCA 
CTC ACG GCA AAT TCA ACG G, re-
verse; AGG GGC GGA GAT GAT GAC 
CC). PCR products were electrophoresed in 
1 % agarose gels containing ethidium bro-
mide and visualized digitally with a UV 
illuminator (AB1500 Printgraph and AE 
6905H Image Saver HR; ATTO Biosci-
ence, Tokyo, Japan). Band intensities were 
semi-quantified using computer software 
(Lane Analyzer 3.0; ATTO Bioscience) 
(Machiya et al., 2007). 
ELISA. Supernatant IL-10 concentra-
tions were measured using a sandwich 
ELISA kit (R&D systems, Minneapolis, 
MN, USA), according to the manufacturer’s 
protocol. After LPS stimulation, the super-
natants were collected and stored at -80 °C 
until measurement. After removal of all 
supernatants, adhered cells were lysed with 
cell lysis buffer (20 mM Tris-HCl, 150 mM 
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1 % 
Triton, 2.5 mM sodium pyrophosphate, 
1 mM β-glycerophosphate, 1 mM Na3VO4, 
and 1 µg/mL leupeptin), and protein con-
centrations determined with the RC DC 
protein assay kit (Bio-Rad, Hercules, CA, 
USA). IL-10 concentrations were adjusted 
for total protein in the cell lysate. 
Immunoblot assay for phosphorylated 
STAT-3 (p-STAT-3). After cells lysis, 15 
µg of protein was blotted onto a PVDF 
membrane (Amersham, Piscataway, NJ, 
USA). The membranes were blocked with 
milk and treated with rabbit phospho-
STAT-3 antibody (1:1000 dilution; Cell 
Signaling Technology, Danvers, MA, USA) 
and horseradish peroxidase (HRP)-conju-
gated anti-rabbit IgG immunoglobulin 
(1:2000 dilution; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Subsequently, 
p-STAT-3 was detected using the ECL plus 
system (Amersham, Piscataway, NJ, USA). 
The membranes were stripped and total 
STAT-3 levels were evaluated using mouse 
STAT-3 antibody (1:1000 dilution; BD 
Transduction Laboratories, Mississauga, 
ON, Canada) and HRP-conjugated anti-
mouse IgG immunoglobulin (1:3333 dilu-
tion; Santa Cruz Biotechnology). 
Time course study of TNF-α gene ex-
pression. RAW264.7 cells were seeded 
onto a 6 cm dish at 1×105 cells/dish and 
pre-treated with vehicle (ethanol) or CAM 
(10 µg/mL) for 3 days, followed by stimula-
tion with LPS (20 ng/mL). Total RNA was 
extracted 0, 6, 12 and 36 h after LPS stimu-
lation, and RT-PCR was performed using 
specific primers for GAPDH and TNF-α 
(forward; AAC TAG TGG TGC CAG CCG 
AT, reverse; CTT CAC AGA GCA ATG 
ACT CC), as described above. 
Statistical analysis. Multiple compare-
sons were performed by 1-way ANOVA 
followed by the Student-Newman-Keuls 
method. In the figures, results are expressed 
as the mean ± SD. Significance was in-
ferred for results for which P < 0.05. Statis-
tical analyses were done using computer 
software (SigmaStat 3.1, Hulinks). 
 
RESULTS 
Expression of IL-10 and IL-10R follow-
ing pre-treatment with a 14-member 
macrolide 
Minimal gene expression of IL-10 was 
observed in the EM-treated RAW cells, 
while no expression was detected in the 
control (vehicle) or CAM-treated 
RAW264.7 cells (Figure 1A, top). IL-10R 
gene expression remained unchanged fol-
lowing EM or CAM treatment, compared 
with the control cells (Figure 1A, middle). 
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Figure 1: The expression of IL-10 and IL-10R 
following treatment with erythromycin (EM) or 
clarithromycin CAM 
(A) Following treatment of RAW264.7 cells with 
EM (10 µg/mL) or CAM (10 µg/mL) for 3 d, IL-
10 and IL-10R expression was evaluated by 
RT-PCR. Minimal IL-10 expression was ob-
served in the EM-treated cells (top panel), but 
not the CAM-treated cells. The expression of IL-
10R remained unchanged (middle panel). 
(B) The macrophage cells were pretreated with 
EM or CAM for 3 d, and stimulated with LPS for 
4 h (total RNA isolation), or 24 h (supernatant 
collection). The expression of IL10 and IL10R 
was evaluated by RT-PCR or sandwich ELISA. 
IL-10 gene expression was enhanced by EM- or 
CAM-treatment compared with the control (ve-
hicle treated) cells after LPS stimulation. Fol-
lowing LPS stimulation, IL-10R expression was 
enhanced by EM treatment, but not by CAM 
treatment. These images are representative of 
6 independent experiments.  
(C) The intensity of each band from (B) was 
semi-quantified as described in Materials and 
Methods.  
(D) Protein concentrations of IL-10 in the su-
pernatant, following LPS stimulation of the 
macrophages, were enhanced by EM- or CAM-
treatment compared with the control cells (n = 5 
for each group). 
All data are expressed as the mean ± SD. #P < 
0.05 vs. vehicle, *P < 0.05 vs. vehicle + LPS 
Expression of IL-10 and IL-10R in 14-
member macrolide-treated RAW264.7 
cells following LPS stimulation  
Following pre-treatment with EM or 
CAM, cells were stimulated with LPS for 
6 h and IL-10 and IL-10R gene expression 
evaluated by RT-PCR. LPS induced IL-10 
and IL-10R gene expression in the macro-
phage cell line. The expression levels of IL-
10 in EM-or CAM-treated cells were 
greater than the control cells after LPS 
stimulation (Figure 1B top, Figure 1C top). 
The expression of IL-10R in the EM-treated 
RAW264.7 cells was higher than the con-
trol cells, while IL-10R expression levels of 
the CAM-treated RAW264.7 cells were 
slightly lower (1.0 µg/mL), or similar 
(10.0 µg/mL) to the control cells after LPS 
stimulation (Figure 1B middle, Figure 1C 
bottom). In addition, IL-10 protein levels in 
the lysates of EM- or CAM-pretreated 
RAW264.7 cells were significantly increa-
sed compared with control cells after LPS 
stimulation. However, IL-10 protein levels 
in the lysates of control cells stimulated 
with LPS were not increased compared 
with unstimulated cells (Figure1D). 
 
Enhanced p-STAT-3 expression follow-
ing LPS stimulation in 14-member mac-
rolide-treated RAW264.7 cells  
Levels of p-STAT-3 after LPS stimula-
tion were enhanced by pre-treatment with 
EM or CAM in a dose-dependent manner 
(Figure 2).  
 
Expression of SOCS-3 after LPS stimula-
tion in 14-member macrolide-treated 
RAW264.7 cells  
Since SOCS-3 is a key molecule in-
volved in the suppression of cytokine sig-
naling by IL-10, we evaluated SOCS-3 
gene expression after LPS stimulation in 
macrolide-pretreated cells. LPS induced 
SOCS-3 gene expression in RAW264.7 
cells. EM and CAM enhanced the expres-
sion of SOCS-3 compared with the control 
cells after LPS stimulation (Figure 3A and 
3B).  
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Figure 2: Levels of phosphorylated (p)-STAT-3 
in LPS stimulated RAW264.7 macrophages 
were enhanced by pre-treatment with macro-
lides  
Following the pre-treatment of RAW264.7 cells 
with erythromycin (EM) or clarithromycin (CAM) 
for 3 d, cells were stimulated with LPS for 8 h. 
Cell lysates were immunoblotted to evaluate p-
STAT-3 and STAT-3 levels, as described in 
Materials and Methods. Levels of p-STAT3 after 
LPS stimulation were enhanced by pre-treat-
ment with either EM or CAM. Representative 
images of 3 independent experiments are 
shown. 
 
Figure 3: Suppressor of cytokine signaling-3 
(SOCS-3) gene expression following LPS 
stimulation in 14-member macrolide-treated 
RAW264.7 cells 
Following the pretreatment of RAW264.7 
macrophages with erythromycin (EM) or 
clarithromycin (CAM) for 3 d, cells were stimu-
lated with LPS for 4 h. RT-PCR was performed 
using specific primers, as described in Materials 
and Methods. (A) SOCS-3 gene expression 
after LPS stimulation was enhanced with EM- 
or CAM-treatment, compared with the control 
cells. Representative images of 6 independent 
experiments are shown. (B) The intensity of 
each band was semi-quantified, as described in 
Materials and Methods.  
All data are expressed as the mean ± SD. #P < 
0.05 vs. vehicle, *P < 0.05 vs. vehicle + LPS 
 
Time course of TNF-α expression after 
LPS stimulation in 14-member macro-
lide-treated RAW264.7 cells  
We pretreated cells with CAM or vehi-
cle, and compared the induction of TNF-α 
in these cells after LPS stimulation. Six 
hours after LPS stimulation, TNF-α expres-
sion in CAM-treated cells was not different 
from the control cells (Figure 4). At 12 h 
after LPS stimulation, TNF-α levels in 
CAM-treated cells were slightly decreased 
compared with control cells, while at 36 h 
after LPS stimulation, TNF-α mRNA levels 
were distinctly lower in the CAM-treated 
RAW264.7 cells than in the control cells 
(Figure 4).  
 
Figure 4: The expression of TNF-α in 
clarithromycin (CAM)-treated RAW264.7 cells 
following LPS stimulation 
After pretreatment of the macrophages with 
CAM (10 µg/mL) or vehicle for 3 d, the cells 
were stimulated with LPS for 0, 6, 12, and 36 h 
and the expression of TNF-α evaluated by RT-
PCR. The expression of TNF-α 6 h after LPS 
stimulation in CAM-treated cells was not differ-
ent to the control cells. At 12 h after LPS stimu-
lation, TNF-α levels in the CAM-treated cells 
were slightly decreased compared with the 
controls, while at 36 h after LPS stimulation, 
TNF-α mRNA levels were clearly lower in the 
CAM-treated RAW264.7 cells than the control 
cells. Representative images of 3 independent 
experiments are shown. 
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We have demonstrated that 14-member 
macrolide treatment enhances the induction 
of IL-10 in macrophages following LPS 
stimulation. Moreover, we observed en-
hanced STAT-3 phosphorylation and 
SOCS-3 expression in EM- and CAM-
treated cells following LPS stimulation. 
Although the level of TNF-α production 6 h 
after LPS stimulation was similar between 
the control and CAM-treated macrophage 
cells, at 36 h after LPS stimulation, the lev-
els of TNF-α in the CAM-treated cells were 
low compared with those of the control 
cells. Thus CAM-treatment may result in 
the early disappearance of TNF-α following 
LPS stimulation, leading to an early recov-
ery of the cells. 
Inflammation is generated by pro-
inflammatory cytokines, and is resolved 
with anti-inflammatory cytokines, such as 
IL-10 (Moore et al., 2001). Lung-specific 
overexpression of IL-10 reduced lung in-
flammation after intra-tracheal administra-
tion of LPS in mice (Spight et al., 2005). 
Pro-inflammatory cytokines activate the 
Janus family kinases associated with their 
connate receptors (Murray, 2007). These 
kinases, associated with their receptors, 
phosphorylate the receptor cytoplasmic 
domains, creating docking sites for Src-
homology2 domain-containing signaling 
proteins (Murray, 2007). The substrates for 
tyrosine phosphorylation are members of 
the STAT family proteins (Murray, 2007). 
Interestingly, the anti-inflammatory cyto-
kine IL-10 also activates STAT-3. Acti-
vated (phosphorylated) STAT-3 translo-
cates into the nucleus and stimulates the 
expression of SOCS-3. Finally, SOCS-3 
binds to the phosphorylated tyrosine resi-
dues of cytokine receptors via their Src-
homology2 domains, thereby negating the 
pro-inflammatory cytokine signals (Yoshi-
mura et al., 2003, 2005). Moreover, the 
ability of IL-10 to induce de novo synthesis 
of SOCS-3 in macrophages correlates with 
its ability to inhibit the expression of many 
genes in these cells, including endotoxin-
inducible cytokines such as TNF-α and IL-
1β (Ito et al., 1999). Thus, the ability of IL-
10 to inhibit gene expression in macro-
phages is associated with its ability to rap-
idly induce synthesis of SOCS-3. 
The mechanism as to how 14-member 
macrolides enhance the expression of IL-10 
following LPS stimulation is still unclear. 
Also, other mechanisms, independent of IL-
10, may be involved in the immunomodula-
tory effects of the 14-member macrolides. 
For example, CAM has been previously 
shown to modify inflammation by suppress-
ing IL-8 production via AP-1 and nuclear 
factor-κB (Kikuchi et al., 2002). Yamaryo 
and colleagues demonstrated that 14-
member macrolides promote the phosphati-
dylserine receptor-dependent phagocytosis 
of apoptotic neutrophils by alveolar macro-
phages (Yamaryo et al., 2003). Recently, it 
was reported that the ability of mannose 
receptor-mediated apoptotic cell clearance 
in alveolar macrophages was enhanced by 
azithromycin, a 15-member macrolide 
(Hodge et al., 2008). However, our study 
indicates that the immunomodulatory ef-
fects of 14-member macrolides on macro-
phages are associated with the IL-
10/SOCS-3 pathway. Demartini and col-
leagues demonstrated that CAM signifi-
cantly increased plasma levels of IL-10 on 
the 3rd and 7th day when compared with 
basal levels in patients with community 
acquired pneumonia (Demartini et al., 
2004). Therefore, the activation of the IL-
10/SOCS-3 pathway may be an important 
mechanism for the immunosuppressive ef-
fects of 14-member macrolides. 
Macrolides are suitable antibiotics for 
treating respiratory tract infections with 
respect to their superior drug delivery into 
lung tissue. The levels of CAM after oral 
administration (500 mg) are reported to be 
4.0 µg/mL in serum, 16.8 mg/kg in bron-
chial biopsies, 20.5 µg/mL in epithelial lin-
ing fluid, and 372.7 µg/mL in alveolar cells 
(Honeybourne et al., 1994). Thus, the con-
centrations of macrolide antibiotics tested 
in this study are compatible with their clini-
cal use. 
As described above, macrolide antibiot-
ics have diverse inflammatory suppressive 
effects on lung cells. Accumulating evi-
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dence suggests that macrolides are effec-
tive, not only for patients with DPB, but 
also for those with cystic fibrosis (McArdle 
and Talwalkar, 2007). Thus, clarifying the 
anti-inflammatory effects of macrolide an-
tibiotics may assist in the development of 
new therapies against many other refractory 
inflammatory diseases. 
We have demonstrated the involvement 
of the IL-10/STAT-3/SOCS-3 pathway in 
the immunomodulatory effects of 14-
member macrolide on macrophages. Our 
results suggest a potent effect of macrolide 
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